Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CAMP4 Therapeutics Corporation (Nasdaq: CAMP) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. CAMP4 identifies itself in these filings as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics and antisense oligonucleotide (ASO) drug candidates to upregulate gene expression for genetic diseases.
Through its Form 8-K filings, CAMP4 reports material events such as securities purchase agreements, private placements, and underwritten offerings of common stock registered on Form S-3. These filings describe how the company expects to use proceeds to support preclinical and clinical development of product candidates, including its SYNGAP1 program, and to fund working capital and general corporate purposes.
CAMP4’s 8-K filings also detail strategic collaboration agreements, including a research, collaboration and license agreement with GSK covering antisense oligonucleotide therapeutics targeting regulatory RNAs for neurodegenerative and kidney disease indications. The filings outline key terms such as exclusive worldwide licenses under certain patents and know-how, upfront payments, potential development and commercial milestones, and tiered royalties on net sales.
Additional 8-Ks address corporate governance and compensation matters, including changes to the board of directors, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and registration rights agreements associated with private placements. As an emerging growth company, CAMP4 uses these reports to communicate significant operational, financing, and collaboration developments.
On Stock Titan, investors can review CAMP4’s filings alongside AI-powered summaries that explain the significance of each document. Users can quickly see highlights from annual and quarterly reports when available, track current reports on Form 8-K, and monitor equity financing terms, collaboration structures, and other regulatory disclosures relevant to CAMP4’s RNA-targeting therapeutic pipeline.
Camp4 Therapeutics director Richard A. Young acquired 15,151 shares of Camp4 Therapeutics Corp (CAMP) in a private placement on 09/11/2025 at $1.65 per share under a Securities Purchase Agreement dated 09/09/2025. After this purchase the reporting person beneficially owned 170,010 shares. The Form 4 was filed individually and executed by an attorney-in-fact. The filing states the purchase involved institutional investors and certain directors, employees and consultants; no derivative transactions or other securities changes are reported.
CAMP Therapeutics reported a private placement and related registration rights, board resignations, and management changes. The company entered into a Purchase Agreement providing for sales of securities in one or two closings and agreed to file an initial registration statement within 60 days of the Initial Closing (and, if applicable, a Second Registration Statement within 30 days of a Second Closing) to permit resale of the issued shares and warrant shares. The company committed to use reasonable best efforts to have registration statements become effective within prescribed SEC timelines and to keep them effective under Rule 415 until resale conditions are met. Cash penalties apply for registration failures and customary reciprocal indemnities were granted. Separately, three directors resigned effective September 9, 2025, Douglas Williams, PhD was named Chair, and Daniel Tardiff, PhD was elevated to Chief Scientific Officer effective October 1, 2025. The securities were issued in a private placement relying on Section 4(a)(2).
CAMP4 Therapeutics is a clinical-stage company developing RNA-targeting therapies using its RAP Platform. The company reported $39.1 million in cash and cash equivalents and $33.8 million of working capital as of June 30, 2025, after raising aggregate net IPO proceeds of $72.4 million (including partial exercise proceeds). CAMP4 recorded a $25.0 million net loss for the six months ended June 30, 2025 (same as prior year) and has an accumulated deficit of $236.8 million. Management estimates existing cash will fund operations into the second quarter of 2026 but concludes there is substantial doubt about the company’s ability to continue as a going concern without additional financing. CAMP4 recognized collaboration revenue including a $0.6 million Fulcrum milestone and $0.9 million and $1.8 million of BioMarin collaboration revenue for the three- and six-month periods of 2025, respectively. The company presented encouraging preclinical SYNGAP program data in May 2025 and plans GLP toxicology studies in Q3 2025 to enable a clinical filing.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider filing
On 06/25/2025, director Richard A. Young received a grant of 9,000 stock options with an exercise price of $1.56 per share. The award was recorded with transaction code “A,” indicating a new acquisition rather than an exercise or sale. All options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual meeting of stockholders, subject to Mr. Young’s continued board service. The options expire on 06/24/2035.
Following the grant, Mr. Young beneficially owns 9,000 derivative securities linked to CAMP common stock, held directly. No open-market purchases or sales of common shares were reported, and no price was paid for the option grant itself.
Key takeaways for investors
- Routine director compensation: single option grant, modest in size.
- No indication of insider buying or selling of existing shares.
- Grant terms align with standard governance practices (10-year life, one-year vesting).
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 detailing a routine director equity grant. On 06/25/2025, director Michael J. Higgins received a stock option covering 9,000 common shares at an exercise price of $1.56 per share. The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual shareholders’ meeting, provided Mr. Higgins remains on the board. The option expires on 06/24/2035. Following the transaction, Mr. Higgins beneficially owns 9,000 derivative securities (options) and disclosed no additional direct or indirect common-stock holdings.
The filing was signed on 06/27/2025 by Josh Mandel-Brehm as Attorney-in-Fact.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider transaction
Director and 10% owner Andrew J. Schwab reported the grant of 9,000 non-qualified stock options on 25 June 2025. The options carry an exercise price of $1.56 per share and expire on 24 June 2035, providing a 10-year term.
- Vesting: The entire award vests on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, subject to Mr. Schwab’s continued board service.
- Ownership status: All 9,000 options are held directly by the reporting person; the filing shows no prior derivative holdings, so the post-grant balance is 9,000 options.
- Transaction code “A” denotes an award rather than an open-market purchase or sale; no cash consideration was paid for the grant (price indicated as $0).
The filing does not disclose any accompanying sales or acquisitions of common shares, nor does it provide earnings or operational data. As such, the Form 4 primarily signals continued equity-based incentive alignment between the director/large shareholder and outside investors.
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 disclosing a routine equity compensation grant to director and 10% owner Amir Nashat. On 06/25/2025 Nashat received 9,000 non-qualified stock options with an exercise price of $1.56 per share. All options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s next annual shareholder meeting, provided Nashat continues to serve on the board through that date. The options carry a 10-year term expiring 06/24/2035 and were reported as direct beneficial ownership. No shares of common stock were bought or sold; the filing reflects only the grant of derivative securities. The size of the award is modest and does not materially change the company’s share count or insider ownership profile.